Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Eli Lilly inks $2.75B deal for AI-discovered drugs from Insilico Medicine

LLY

$1,157.07

+$0.44 +0.04%

Eli Lilly inks $2.75B deal for AI-discovered drugs from Insilico Medicine

Market News

29 Mar 2026

CNBC

View Source

Bullish

Eli Lilly has agreed to a $2.75 billion deal with Hong Kong-based Insilico Medicine to commercialize drugs developed using AI. Insilico will receive $115 million upfront, with additional payments tied to milestones and royalties on sales. The partnership builds on their 2023 collaboration and aims to accelerate drug discovery by combining Insilico's AI capabilities with Lilly's clinical expertise. Insilico has developed 28 AI-discovered drugs, nearly half in clinical stages, highlighting AI's growing role in pharmaceutical innovation.

More News (LLY)

Eli Lilly stock could grow 76% in 3 years driven by blockbuster drugs and new sales channels.

Eli Lilly's stock is projected to grow about 76% over the next three years, reaching around $2,091 per share. This growth is fueled by strong revenue increases from blockbuster drugs like Mounjaro and Zepbound, which contributed $6.7 billion in new r...

Analyst Insights

Bullish

1 day ago